Greater Potential Benefit In Overall Survival For Eribulin Compared With Capecitabine For Metastatic Breast Cancer

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO Annual Meeting...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news